Resunab, Potential Scleroderma Treatment, Shows Ability to Stop Inflammation in Early Clinical Trial. Corbus Pharmaceuticals reported new findings supporting the anti–inflammatory actions of its lead compound Resunab (JBT-101), which is currently being explored in a clinical trial for scleroderma. Scleroderma News, 09/29/2016. (Also see Scleroderma Clinical Trials)
Antibodies That Attack Inflammatory Immune Cells May Work to Treat Scleroderma. Antibodies against a protein selectively expressed on certain types of immune system cells were seen to prevented fibrosis in rodent models of scleroderma and lung fibrosis. Scleroderma News, 09/27/2016. (Also see Antibodies)
A Proteome derived longitudinal pharmacodynamic biomarker for diffuse systemic sclerosis (SSc) skin. In this study a large array of proteins were discovered, not previously associated with SSc, that provide insights into pathogenesis and potential targets for therapeutic intervention. PubMed, J Invest Dermatol, 09/14/2016. (Also see Prognosis and Mortality)
Nintedanib receives orphan drug designation for systemic sclerosis. The FDA has granted Orphan Drug Designation to Boehringer Ingelheim's nintedanib for the treatment of (SSc), including associated interstitial lung disease (SSc–ILD). Pharmacy Times, 09/27/2016. (Also see Scleroderma Clinical Trials)
A personalized physical therapy program or usual care for patients with systemic sclerosis (SSc): A randomized controlled trial. A personalized physical therapy program did not reduce disability at 12 months but had short–term benefits for patients with SSc. PubMed, Arthritis Care Res (Hoboken), 10/12/2016. (Also see Skin Fibrosis)
Risk factors for development of pulmonary arterial hypertension (PAH) in Australian systemic sclerosis patients: results from a large multicenter cohort study. This model identifies a subset of patients at an appreciably higher risk of developing PAH, who should be screened and would in future, benefit from preventative therapies. PubMed, BMC Pulm Med, 2016 Sep 27;16(1):134. (Also see Pulmonary Hypertension Diagnosis)
Mechanistic insight into the norepinephrine (NE)–induced fibrosis in systemic sclerosis (SSc). These results suggest that cold exposure and/or emotional stress–induced NE might contribute to the skin fibrosis via potentiation of IL-6 production from fibroblasts in SSc. PMC, Sci Rep, 2016; 6: 34012. (Also see Interleukins and Fibroblasts)
Aberrant immune response with consequent vascular and connective tissue remodeling – causal to scleroderma and associated syndromes? Therapeutic helminth infection or treatment with parasite–derived response modifiers could be promising new management tools for autoimmune connective tissue diseases. PubMed, Curr Opin Rheumatol, 2016 Nov;28(6):571-6. (Also see Prognosis of Pulmonary Hypertension)
Beneficial effects of long–term treatment with bosentan on the development of pulmonary arterial hypertension in patients with systemic sclerosis. Long–term treatment with bosentan reduces the risk of developing PAH in patients with systemic sclerosis. PubMed, J Int Med Res, 2016 Sep;44(1 suppl):85-89. (Also see Tracleer (Bosentan))
Dendritic cells (DC) maintain dermal adipose–derived stromal cells (ADSCs) in skin fibrosis. These findings provide insight into the effects of skin fibrosis on the dermal white adipose tissue ADSCs, identify a DC-ADSC survival axis in fibrotic skin, and suggest an approach for improving mesenchymal stromal cell therapy in scleroderma and other diseases. PubMed, 10/10/2016. (Also see Dendritic Cells)
United Way of Central New Mexico
United Way of Snohomish County
See ISN News for recent donors, including Juliet Youkhana; and donations in loving memory of Jim Miller and Arlene Marie Petulla.
Click Here to Donate or Shop
or click on the floating green DONATE sclero.org button.
SCLERO.ORG is the world leader for trustworthy research, support, education and awareness for scleroderma and related illnesses, such as pulmonary hypertension. We are a service of the nonprofit International Scleroderma Network (ISN), which is a 501(c)(3) U.S.-based public charitable foundation, established in 2002. Meet Our Team, or Volunteer. Donations may also be mailed to: